A clinical trial research program offering Australians with blood cancer genomic screening and potential access to precision medicines.
MoST 15 substudies 33-34: Durvalumab plus Acalabrutinib
Title: A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma
The aim of this MoST-LLy substudy is to assess the clinical activity of durvalumab and acalabrutinib in patients with high grade B cell lymphoma.
Eligible Population: Adult patients with pathologically confirmed high grade B cell lymphoma enrolled in the MoST program for molecular screening are eligible for this study.
Substudy status: recruiting
ANZCTR registration number: ACTRN12621000507886ANZCTR registration details